Intervention Summary
Co-administration of multi-strain probiotics (Bifidobacterium, Lactobacillus, Enterococcus, Bacillus cereus) alongside PPI therapy to mitigate PPI-induced gut dysbiosis. This addresses the treatment paradox: PPIs improve esophageal inflammation but worsen gut microbial balance.
Evidence
RCT (Yin 2025)
- Design: RCT, n=60 (30 per group), 8 weeks
- Intervention: Rabeprazole + CBLEB (Combined Bifidobacterium, Lactobacillus, Enterococcus, Bacillus cereus) vs. rabeprazole alone
- Bifidobacterium: 6.3→9.2 lgCFU/g (probiotic) vs. 6.6→8.4 (control), P<0.05
- CRP: Significantly lower in probiotic group (P=0.0486); CRP and GerdQ linearly correlated (R2=0.65)
- Adverse reactions: 6.6% vs. 16.6% (P<0.01) — probiotics reduced GI side effects
- Source: [1]
Pediatric Evidence
In children: PPI + probiotics resulted in only 6.2% gut dysbiosis vs. 56.2% with PPI + placebo — a 9-fold reduction in dysbiosis incidence.
Clinical Context
PPIs are the standard first-line GERD treatment and cannot simply be avoided. But PPIs have the most significant microbiome impact after antibiotics. Co-administering probiotics is a practical strategy that maintains PPI efficacy while protecting the gut microbiome. This should be standard practice rather than an afterthought.